United States: Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab) - Goodwin Procter LLP

Mondaq

05 Mar 2024 0 shares 1 views

United States: Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab) - Goodwin Procter LLP

Mondaq

Published 05 Mar 2024

On February 12, 2024, Chugai, Genentech, and Hoffmann-La Roche filed a motion for voluntary dismissal of their appeals of the PTAB's Final Written Decisions in IPR2022-00578 and IPR2022-00579.

Full Article

United States: Fresenius Kabi Announces FDA Approval Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA - Goodwin Procter LLP

On March 7, Fresenius Kabi announced that the FDA has approved its tocilizumab biosimilar, TYENNE (tocilizumab-aazg) for..

Mondaq 19 Mar 2024

United States: Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab) - Goodwin Procter LLP

United States: Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab) - Goodwin Procter LLP

You might like

Related news coverage

United States: Fresenius Kabi Announces FDA Approval Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA - Goodwin Procter LLP

Advertisement